SEC Form 4 · accession 0001192482-18-000182
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Karen Flynn
Director
Period of report
May 4, 2018
Accepted (ET)
May 8, 2018 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 4, 2018 | A | 6,183 | $0.00 | A | 6,983 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $11.32 | May 4, 2018 | A | 5,742 | A | — | May 4, 2028 | Common Stock | 5,742 | 5,742 | D |
Explanation of responses
- F1All shares of common stock are represented by unvested restricted stock units that will vest on May 4, 2019. Vested shares will be delivered to the reporting person within 30 days following the vesting date.
- F2The stock option will vest on May 4, 2019.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney